HJM-561

HJM-561 is a selective and effective orally active EGFR PROTAC degrader. HJM-561 is able to overcome the triple EGFR mutations that are resistant to Osimertinib. HJM-561 exhibits potent degradation of EGFR Del19/T790M/C797S (DC50: 9.2 nM) and L858R/T790M/C797S (DC50: 5.8 nM), and has anti-tumor activity (pink: EGFR ligand; blue: CRBN ligand black: linker)[1].


Cat. No.: EX-A14787	Purity: >98%

	Chemical structure of HJM-561

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	get quote	Inquire
500mg	get quote	Inquire
1g	get quote

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2570251-68-0
Purity	>98%
Formula	C45H51ClN9O5P
Mol Weight	864.371
Color	Off-white to light yellow
State	Solid
Solubility	soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder -20℃, 3 years; In solvent -20℃, 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Du Y, et al. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations. Mol Cancer Ther. 2022 Jul 5;21(7):1060-1066.
CoA	CoA of HJM-561

Smiles:	COC1=C(C=CC(=C1)N2CCC(CC2)N3CCN(CC3)CCC#CC4=C5CN(C(=O)C5=CC=C4)C6CCC(=O)NC6=O)NC7=NC=C(C(=N7)NC8=CC=CC=C8P(=O)(C)C)Cl


		Search